Effective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study

References

• PierriF, DufourC. Management of aplastic anemia after failure of frontline immunosuppression. Expert Rev Hematol. 2019;12(10):809–819. doi:10.1080/17474086.2019.164500331311355
   PubMed Web of Science ®Google Scholar
• MarshJ, SchrezenmeierH, MarinP, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93(7):2191–2195.10090926
   PubMed Web of Science ®Google Scholar
• ZhuXF, HeHL, WangSQ, et al. Current treatment patterns of aplastic anemia in China: a prospective cohort registry study. Acta Haematol. 2019;142(3):162–170. doi:10.1159/00049906531091521
   PubMed Web of Science ®Google Scholar
• AlashkarF, OelmullerM, Herich-TerhurneD, et al. Immunosuppressive therapy (IST) in adult patients with acquired aplastic anemia (AA): A single-center experience over the past 15 years. Eur J Haematol. 2019;103(1):18–25. doi:10.1111/ejh.1323530977158
   PubMed Web of Science ®Google Scholar
• TongJ, VialeM, BacigalupoA, EspositoM. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. Haematologica. 1992;77(4):369–370.1385279
   PubMed Web of Science ®Google Scholar
• YagasakiH, KojimaS, YabeH, et al. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Biol Blood Marrow Transplant. 2009;15(12):1603–1608. doi:10.1016/j.bbmt.2009.08.01219896085
   PubMed Web of Science ®Google Scholar
• ZhuX, GuanJ, XuJ, et al. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults. Blood Cells Mol Dis. 2014;53(3):157–160. doi:10.1016/j.bcmd.2014.04.00824931461
   PubMed Web of Science ®Google Scholar
• AlsultanA, GoldenbergNA, KaiserN, GrahamDK, HaysT. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer. 2009;52(5):626–630. doi:10.1002/pbc.2192619148946
   PubMed Web of Science ®Google Scholar
• InamotoY, FlowersME, WangT, et al. Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. Biol Blood Marrow Transplant. 2015;21(10):1776–1782. doi:10.1016/j.bbmt.2015.05.02326033280
   PubMed Web of Science ®Google Scholar
• MacartneyC, FreilichM, OdameI, CharpentierK, DrorY. Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A. Pediatr Blood Cancer. 2009;52(4):525–527. doi:10.1002/pbc.2175119058202
   PubMed Web of Science ®Google Scholar
• CamittaBM, StorbR, ThomasED. Aplastic anemia (second of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306(12):712–718. doi:10.1056/NEJM1982032530612047038485
   PubMed Web of Science ®Google Scholar
• LinS, HouL, LiuS, et al. Roles of regulatory T cells in the pathogenesis of pediatric aplastic anemia. Pediatr Hematol Oncol. 2019;36(4):198–210. doi:10.1080/08880018.2019.162196831287345
   PubMed Web of Science ®Google Scholar
• DongQE, FuR, LiuCY, et al. [Inhibitory effects of tacrolimus on effector T cells from patients with severe aplastic anemia]. Zhonghua Yi Xue Za Zhi. 2013;93(20):1541–1545. Chinese.24028719
   PubMedGoogle Scholar
• VallejoC, IniestaP, MoraledaJM. Resolution of cyclosporine-induced gingival hyperplasia resistant to azithromycin by switching to tacrolimus. Haematologica. 2001;86(1):110.11146586
   PubMedGoogle Scholar
• TisdaleJF, DunnDE, MaciejewskiJ. Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. Semin Hematol. 2000;37(1):102–109. doi:10.1016/S0037-1963(00)90034-910676915
   PubMed Web of Science ®Google Scholar
• FattizzoB, LevatiG, CassinR, BarcelliniW. Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation. Drugs. 2019;79(12):1305–1319. doi:10.1007/s40265-019-01159-031292909
   PubMed Web of Science ®Google Scholar
• EcsediM, LenglineE, Knol-BoutC, et al. Use of eltrombopag in aplastic anemia in Europe. Ann Hematol. 2019;98(6):1341–1350. doi:10.1007/s00277-019-03652-830915499
   PubMed Web of Science ®Google Scholar
• ChengH, WangX, ZhouD, CaoJ, LarochelleA, XuKL. Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia. Ann Hematol. 2019;98(8):2009–2011. doi:10.1007/s00277-019-03658-230891613
   PubMed Web of Science ®Google Scholar
• LiuJY, YouRX, GuoM, et al. Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: a meta-analysis and economics evaluation. Am J Ther. 2016;23(3):e810–824. doi:10.1097/MJT.000000000000015025299636
   PubMed Web of Science ®Google Scholar
• MudumaG, SaundersR, OdeyemiI, PollockRF. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PLoS One. 2016;11(11):e0160421.27812112
   PubMed Web of Science ®Google Scholar
• HalloranPF, MadrenasJ. The mechanism of action of cyclosporine: a perspective for the 90’s. Clin Biochem. 1991;24(1):3–7. doi:10.1016/0009-9120(91)90063-K1711939
   PubMed Web of Science ®Google Scholar
• BaiYJ, WangLL, CaiB, ZouYG, FengWH, YanLN. [Regulatory function of tacrolimus and CsA on CD4/CD8 T lymphocyte subgroups and costimulators on them in allo-liver recipients]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24(10):989–992. Chinese.18845086
   PubMedGoogle Scholar
• MirouxC, MoralesO, GhazalK, et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation. 2012;94(2):123–131. doi:10.1097/TP.0b013e3182590d8f22743548
   PubMed Web of Science ®Google Scholar
• SolomouEE, RezvaniK, MielkeS, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007;110(5):1603–1606.17463169
   PubMed Web of Science ®Google Scholar
• KordastiS, CostantiniB, SeidlT, et al. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood. 2016;128(9):1193–1205. doi:10.1182/blood-2016-03-70370227281795
   PubMed Web of Science ®Google Scholar
• HamaA, TakahashiY, MuramatsuH, et al. Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine. Haematologica. 2015;100(11):1426–1433. doi:10.3324/haematol.2015.12855326273061
   PubMed Web of Science ®Google Scholar